Two mammalian serpins, alpha 1 antitrypsin (A1AT, SERPINA1), and complement 1 inhibitor (C1Inh, SERPING1) are in clinical trials as potential treatments for SARS‐CoV‐2 ARDS (Wettstein et al, 2021; Karnaukhova, 2022). This evidence concerns the gene SERPING1 and acute respiratory distress syndrome.